- Tonix Pharmaceuticals Holding Corp to Host KOL Webinar TranscriptJan 31, 2024
- Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference TranscriptOct 19, 2023
- Tonix Pharmaceuticals Holding Corp At The June 1st Virtual Investor Summit TranscriptJun 01, 2023
- Tonix Pharmaceuticals Holding Corp At Investor Summit (Virtual) TranscriptMar 29, 2023
- Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio TranscriptFeb 23, 2023
- Tonix Pharmaceuticals Holding Corpinterview with Dr. Seth Lederman, MD, and CEO TranscriptFeb 13, 2023
- Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies TranscriptFeb 01, 2023
- Tonix Pharmaceuticals Holding Corp at EBD Group Biotech Showcase TranscriptJan 10, 2023
- Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference TranscriptOct 26, 2022
- Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit TranscriptMay 04, 2022
- Tonix Pharmaceuticals Holding Corp at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 27, 2022
- Tonix Pharmaceuticals Holding Corp at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 21, 2022
- Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) CEO & Investor Conference (Virtual) - Virtual Presentation TranscriptFeb 14, 2022
- Tonix Pharmaceuticals Holding Corp at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference TranscriptJan 14, 2021
- Tonix Pharmaceuticals Holding Corp Business Update TranscriptDec 07, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Network Virtual Conference TranscriptAug 06, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase TranscriptApr 29, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase TranscriptApr 22, 2020
- Tonix Pharmaceuticals Holding Corp at Tarsier Capital Management Spring Summit TranscriptMar 25, 2020
- Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference TranscriptFeb 18, 2020
Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference Transcript
Thank you all for coming. I am Seth Lederman, the CEO of Tonix Pharmaceuticals, and we're on NASDAQ. So, this is our standard Safe Harbor statement. I will be making forward-looking statements. Tonix is a NASDAQ company. We recently did a financing last week. We just closed on a financing, it's a very exciting time for our company. Our lead program is a treatment for Fibromyalgia. That's in Phase-3 development and it's a very big year for us in this program. The Phase-3 program will have an interim analysis in the third quarter of this year, and we expect top line data in the first half of 2021.
So, I'm going to spend most of the time talking about our lead program in fibromyalgia, but I also want to take you through our pipeline. This is the three main programs that we have in central nervous system development. And the first one TNX-102 SL, we are pursuing for three different indications, fibromyalgia, which is in Phase-3 that I mentioned, bedtime treatment for agitation in Alzheimer's, which we have in IND, but have not
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)